Stĕpán J, Wilczek H, Justová V, Havránek T, Skrha F, Wildtová Z, Formánková J, Pacovský V
Horm Metab Res. 1982 Feb;14(2):98-100. doi: 10.1055/s-2007-1018934.
In oral sulfonylurea treated diabetics, decreased plasma 25-hydroxycholecalciferol and increased activity of bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion was found when compared with control subjects. In stepwise regression analysis significant relationships were found between bone isoenzyme, urinary hydroxyproline excretion, serum calcium levels and blood glucose levels. The partial correlation and multivariate regression analysis showed that in oral sulfonylurea treated patients, but not in insulin treated patients, the activity of bone isoenzyme of serum alkaline phosphatase was significantly inverse dependent on the 25-hydroxycholecalciferol levels in plasma. Oral sulfonylurea agents which are known to induce the hepatic microsomal system seem to be an additional factor to poor control of diabetes, leading to osteopathy.
与对照组相比,口服磺脲类药物治疗的糖尿病患者血浆25-羟胆钙化醇水平降低,血清碱性磷酸酶骨同工酶活性增加,尿羟脯氨酸排泄增加。逐步回归分析发现骨同工酶、尿羟脯氨酸排泄、血清钙水平和血糖水平之间存在显著相关性。偏相关和多元回归分析表明,在口服磺脲类药物治疗的患者中,而非胰岛素治疗的患者中,血清碱性磷酸酶骨同工酶活性与血浆中25-羟胆钙化醇水平呈显著负相关。已知可诱导肝微粒体系统的口服磺脲类药物似乎是导致糖尿病控制不佳进而引发骨病的另一个因素。